Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 104 clinical trials
Featured trial
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom

segmental vitiligo
phototherapy
  • 17 views
  • 23 Jul, 2022
  • 7 locations
Featured trial
The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis (SCRATCH-AD)

The purpose of the study is to evaluate the effect of ruxolitinib cream on itch in participants with Atopic Dermatitis.

  • 0 views
  • 29 Jul, 2022
  • 1 location
Featured trial
Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

People with Myelofibrosis are asked to participate in a research study being conducted by Montefiore Medical Center.

  • 0 views
  • 06 Aug, 2021
  • 1 location
Featured trial
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in subjects with myelofibrosis.  

myelofibrosis
myeloproliferative disorders
leukemia
  • 172 views
  • 10 May, 2022
  • 9 locations
Featured trial
Study of Ruxolitinib Cream in Children With Atopic Dermatitis

Open-label, BID application to all affected areas identified at BSLN for 4 weeks (maximum use trial (MUsT) period). The next 4 weeks (treatment extension period) will be applied BID to active lesions only for the next 4 weeks for a total treatment period of 8 weeks. Eligible participants will be …

  • 0 views
  • 21 Mar, 2022
  • 16 locations
Featured trial
INCB 18424-303: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE-AD1)

A Phase 3, randomized (2:2:1), double-blind, 8-week vehicle control efficacy and safety study of ruxolitinib followed by a randomized, double-blind, 44-week long term safety (LTS) extension period

atopic dermatitis
eczema
atopic dermatitis/eczema
  • 582 views
  • 10 May, 2022
  • 19 locations
Featured trial
INCB 18424-304: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE-AD2) for 304

A Phase 3, randomized (2:2:1), double-blind, 8-week vehicle control efficacy and safety study of ruxolitinib followed by a randomized, double-blind, 44-week long term safety (LTS) extension

dermatitis
atopic dermatitis
eczema
atopic dermatitis/eczema
  • 423 views
  • 03 May, 2022
  • 11 locations
Featured trial
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease

A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease

bone marrow transplant
transplant conditioning
stem cell transplant
stem cell transplantation
nutritional supplement
  • 322 views
  • 08 Dec, 2020
  • 1 location
Featured trial
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. INCB000928 tablets will be administered orally at a starting dose of 50 mg QD in

anemia
  • 81 views
  • 10 May, 2022
  • 2 locations
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera (MITHRIDATE)

The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a

ruxolitinib
hydroxyurea
interferon
  • 1 views
  • 03 Mar, 2022
  • 2 locations